HORMA domain containing 1Genealiases: CT46 · NOHMA
Q-omics provides the consensus-scored HORMAD1 profile across patient tissues and cancer cell-line models. HORMAD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HORMAD1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HORMAD1 RNA expression shows 14,517 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where HORMAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HORMAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HORMAD1 survival associations across molecular data types. HORMAD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HORMAD1 RNA expression–survival associations across cancer types. High HORMAD1 expression shows unfavorable associations in KIRC, LGG and THCA, but favorable associations in HNSC, READ and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for HORMAD1 RNA expression.
This table summarizes HORMAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HORMAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HORMAD1 shows higher tumor expression in KIRC, LUAD, HNSC, LUSC, BLCA and BRCA. The KIRC box plot shows higher HORMAD1 RNA expression in tumor versus normal tissue (log2 FC = +0.133, t-test p < 0.001).
This table shows molecular features associated with HORMAD1 in patient tissues and cancer cell lines. In patient samples, HORMAD1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, HORMAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
